Shares of REDHILL BIOPHAR/S (NASDAQ:RDHL) have received a consensus recommendation of “Buy” from the six ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $20.65.
A number of research firms have recently issued reports on RDHL. Zacks Investment Research raised shares of REDHILL BIOPHAR/S from a “hold” rating to a “strong-buy” rating and set a $9.25 price target for the company in a research report on Wednesday. HC Wainwright set a $36.00 price target on shares of REDHILL BIOPHAR/S and gave the stock a “buy” rating in a research report on Tuesday, October 23rd. Finally, ValuEngine lowered shares of REDHILL BIOPHAR/S from a “hold” rating to a “sell” rating in a research report on Thursday, October 11th.
A number of large investors have recently added to or reduced their stakes in RDHL. Clear Harbor Asset Management LLC acquired a new position in REDHILL BIOPHAR/S in the third quarter worth approximately $323,000. JPMorgan Chase & Co. increased its holdings in REDHILL BIOPHAR/S by 61.4% in the third quarter. JPMorgan Chase & Co. now owns 73,878 shares of the biotechnology company’s stock worth $652,000 after buying an additional 28,102 shares during the last quarter. ARK Investment Management LLC increased its holdings in REDHILL BIOPHAR/S by 8.6% in the second quarter. ARK Investment Management LLC now owns 112,648 shares of the biotechnology company’s stock worth $961,000 after buying an additional 8,894 shares during the last quarter. Creative Planning increased its holdings in REDHILL BIOPHAR/S by 16.1% in the third quarter. Creative Planning now owns 162,950 shares of the biotechnology company’s stock worth $1,439,000 after buying an additional 22,561 shares during the last quarter. Finally, 683 Capital Management LLC increased its holdings in REDHILL BIOPHAR/S by 22.8% in the second quarter. 683 Capital Management LLC now owns 2,042,654 shares of the biotechnology company’s stock worth $17,424,000 after buying an additional 378,751 shares during the last quarter. Hedge funds and other institutional investors own 22.80% of the company’s stock.
NASDAQ RDHL opened at $8.56 on Friday. The company has a market capitalization of $170.40 million, a PE ratio of -3.29 and a beta of 0.84. REDHILL BIOPHAR/S has a 52-week low of $4.30 and a 52-week high of $11.49.
REDHILL BIOPHAR/S (NASDAQ:RDHL) last posted its quarterly earnings results on Thursday, August 30th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). The company had revenue of $2.35 million during the quarter, compared to analysts’ expectations of $2.77 million. REDHILL BIOPHAR/S had a negative return on equity of 133.07% and a negative net margin of 564.71%. As a group, research analysts anticipate that REDHILL BIOPHAR/S will post -1.69 EPS for the current fiscal year.
About REDHILL BIOPHAR/S
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs.
See Also: What is the Dividend Aristocrat Index?
Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.